Long-term outcome of pyogenic vertebral osteomyelitis: A cohort study of 260 patients

Arjun Gupta, Todd J. Kowalski, Douglas R. Osmon, Mark Enzler, James M. Steckelberg, Paul M. Huddleston, Ahmad Nassr, Jayawant Mandrekar, Elie F. Berbari

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background. The long-term outcome of patients with pyogenic vertebral osteomyelitis (PVO) has not been fully assessed. Methods. We conducted a retrospective cohort study to describe the long-term outcome of PVO and to assess risk factors for treatment failure in patients evaluated at our institution between 1994 and 2002. Patients were observed until July 1, 2013. Results. Two hundred sixty patients with PVO were included in this study. Twenty-seven percent (70) of patients developed their infection after an invasive spinal procedure. Staphylococcus aureus accounted for 40% (103) of infections. Forty-nine percent (128) of patients underwent spinal surgery as part of their initial therapy. The median duration of parenteral antimicrobial therapy was 42 days (interquartile range, 38-53). The estimated 2-, 5-, and 10- year cumulative probability of treatment failure-free survival was 72%, 69%, and 69%, respectively. Seventy-five percent of patients who developed treatment failure did so within 4.7 months of diagnosis. Residual neurological defects and persistent back pain were seen in 16% and 32% of patients, respectively. In a multivariate analysis, longer duration of symptoms before diagnosis and having an infection with S. aureus were associated with increased risk of treatment failure. Conclusions. Increasing duration of symptoms and infection with S. aureus were associated with treatment failure in patients with PVO. Most treatment failures occurred early after initiation of treatment. Pyogenic vertebral osteomyelitis is associated with a high 2-year failure rate. Persistent neurological deficits and back pain are common after therapy.

Original languageEnglish (US)
Article numberofu107
JournalOpen Forum Infectious Diseases
Volume1
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Osteomyelitis
Cohort Studies
Treatment Failure
Staphylococcus aureus
Back Pain
Infection
Therapeutics
Multivariate Analysis
Retrospective Studies
Survival

Keywords

  • Outcome
  • Spondylodiscitis
  • Treatment failure
  • Vertebral osteomyelitis

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Cite this

Gupta, A., Kowalski, T. J., Osmon, D. R., Enzler, M., Steckelberg, J. M., Huddleston, P. M., ... Berbari, E. F. (2014). Long-term outcome of pyogenic vertebral osteomyelitis: A cohort study of 260 patients. Open Forum Infectious Diseases, 1(3), [ofu107]. https://doi.org/10.1093/ofid/ofu107

Long-term outcome of pyogenic vertebral osteomyelitis : A cohort study of 260 patients. / Gupta, Arjun; Kowalski, Todd J.; Osmon, Douglas R.; Enzler, Mark; Steckelberg, James M.; Huddleston, Paul M.; Nassr, Ahmad; Mandrekar, Jayawant; Berbari, Elie F.

In: Open Forum Infectious Diseases, Vol. 1, No. 3, ofu107, 2014.

Research output: Contribution to journalArticle

Gupta, A, Kowalski, TJ, Osmon, DR, Enzler, M, Steckelberg, JM, Huddleston, PM, Nassr, A, Mandrekar, J & Berbari, EF 2014, 'Long-term outcome of pyogenic vertebral osteomyelitis: A cohort study of 260 patients', Open Forum Infectious Diseases, vol. 1, no. 3, ofu107. https://doi.org/10.1093/ofid/ofu107
Gupta A, Kowalski TJ, Osmon DR, Enzler M, Steckelberg JM, Huddleston PM et al. Long-term outcome of pyogenic vertebral osteomyelitis: A cohort study of 260 patients. Open Forum Infectious Diseases. 2014;1(3). ofu107. https://doi.org/10.1093/ofid/ofu107
Gupta, Arjun ; Kowalski, Todd J. ; Osmon, Douglas R. ; Enzler, Mark ; Steckelberg, James M. ; Huddleston, Paul M. ; Nassr, Ahmad ; Mandrekar, Jayawant ; Berbari, Elie F. / Long-term outcome of pyogenic vertebral osteomyelitis : A cohort study of 260 patients. In: Open Forum Infectious Diseases. 2014 ; Vol. 1, No. 3.
@article{ab4998df22e04f45b46d6d6ee2795f72,
title = "Long-term outcome of pyogenic vertebral osteomyelitis: A cohort study of 260 patients",
abstract = "Background. The long-term outcome of patients with pyogenic vertebral osteomyelitis (PVO) has not been fully assessed. Methods. We conducted a retrospective cohort study to describe the long-term outcome of PVO and to assess risk factors for treatment failure in patients evaluated at our institution between 1994 and 2002. Patients were observed until July 1, 2013. Results. Two hundred sixty patients with PVO were included in this study. Twenty-seven percent (70) of patients developed their infection after an invasive spinal procedure. Staphylococcus aureus accounted for 40{\%} (103) of infections. Forty-nine percent (128) of patients underwent spinal surgery as part of their initial therapy. The median duration of parenteral antimicrobial therapy was 42 days (interquartile range, 38-53). The estimated 2-, 5-, and 10- year cumulative probability of treatment failure-free survival was 72{\%}, 69{\%}, and 69{\%}, respectively. Seventy-five percent of patients who developed treatment failure did so within 4.7 months of diagnosis. Residual neurological defects and persistent back pain were seen in 16{\%} and 32{\%} of patients, respectively. In a multivariate analysis, longer duration of symptoms before diagnosis and having an infection with S. aureus were associated with increased risk of treatment failure. Conclusions. Increasing duration of symptoms and infection with S. aureus were associated with treatment failure in patients with PVO. Most treatment failures occurred early after initiation of treatment. Pyogenic vertebral osteomyelitis is associated with a high 2-year failure rate. Persistent neurological deficits and back pain are common after therapy.",
keywords = "Outcome, Spondylodiscitis, Treatment failure, Vertebral osteomyelitis",
author = "Arjun Gupta and Kowalski, {Todd J.} and Osmon, {Douglas R.} and Mark Enzler and Steckelberg, {James M.} and Huddleston, {Paul M.} and Ahmad Nassr and Jayawant Mandrekar and Berbari, {Elie F.}",
year = "2014",
doi = "10.1093/ofid/ofu107",
language = "English (US)",
volume = "1",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Long-term outcome of pyogenic vertebral osteomyelitis

T2 - A cohort study of 260 patients

AU - Gupta, Arjun

AU - Kowalski, Todd J.

AU - Osmon, Douglas R.

AU - Enzler, Mark

AU - Steckelberg, James M.

AU - Huddleston, Paul M.

AU - Nassr, Ahmad

AU - Mandrekar, Jayawant

AU - Berbari, Elie F.

PY - 2014

Y1 - 2014

N2 - Background. The long-term outcome of patients with pyogenic vertebral osteomyelitis (PVO) has not been fully assessed. Methods. We conducted a retrospective cohort study to describe the long-term outcome of PVO and to assess risk factors for treatment failure in patients evaluated at our institution between 1994 and 2002. Patients were observed until July 1, 2013. Results. Two hundred sixty patients with PVO were included in this study. Twenty-seven percent (70) of patients developed their infection after an invasive spinal procedure. Staphylococcus aureus accounted for 40% (103) of infections. Forty-nine percent (128) of patients underwent spinal surgery as part of their initial therapy. The median duration of parenteral antimicrobial therapy was 42 days (interquartile range, 38-53). The estimated 2-, 5-, and 10- year cumulative probability of treatment failure-free survival was 72%, 69%, and 69%, respectively. Seventy-five percent of patients who developed treatment failure did so within 4.7 months of diagnosis. Residual neurological defects and persistent back pain were seen in 16% and 32% of patients, respectively. In a multivariate analysis, longer duration of symptoms before diagnosis and having an infection with S. aureus were associated with increased risk of treatment failure. Conclusions. Increasing duration of symptoms and infection with S. aureus were associated with treatment failure in patients with PVO. Most treatment failures occurred early after initiation of treatment. Pyogenic vertebral osteomyelitis is associated with a high 2-year failure rate. Persistent neurological deficits and back pain are common after therapy.

AB - Background. The long-term outcome of patients with pyogenic vertebral osteomyelitis (PVO) has not been fully assessed. Methods. We conducted a retrospective cohort study to describe the long-term outcome of PVO and to assess risk factors for treatment failure in patients evaluated at our institution between 1994 and 2002. Patients were observed until July 1, 2013. Results. Two hundred sixty patients with PVO were included in this study. Twenty-seven percent (70) of patients developed their infection after an invasive spinal procedure. Staphylococcus aureus accounted for 40% (103) of infections. Forty-nine percent (128) of patients underwent spinal surgery as part of their initial therapy. The median duration of parenteral antimicrobial therapy was 42 days (interquartile range, 38-53). The estimated 2-, 5-, and 10- year cumulative probability of treatment failure-free survival was 72%, 69%, and 69%, respectively. Seventy-five percent of patients who developed treatment failure did so within 4.7 months of diagnosis. Residual neurological defects and persistent back pain were seen in 16% and 32% of patients, respectively. In a multivariate analysis, longer duration of symptoms before diagnosis and having an infection with S. aureus were associated with increased risk of treatment failure. Conclusions. Increasing duration of symptoms and infection with S. aureus were associated with treatment failure in patients with PVO. Most treatment failures occurred early after initiation of treatment. Pyogenic vertebral osteomyelitis is associated with a high 2-year failure rate. Persistent neurological deficits and back pain are common after therapy.

KW - Outcome

KW - Spondylodiscitis

KW - Treatment failure

KW - Vertebral osteomyelitis

UR - http://www.scopus.com/inward/record.url?scp=84978328163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978328163&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofu107

DO - 10.1093/ofid/ofu107

M3 - Article

AN - SCOPUS:84978328163

VL - 1

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

SN - 2328-8957

IS - 3

M1 - ofu107

ER -